Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Syros Pharmaceuticals (SYRS).
At Syros Pharmaceuticals’ 2024 Annual Meeting, stockholders greenlit a significant amendment to the Equity Incentive Plan, adding 1,750,000 shares for issuance. Additionally, they voted for the election of three Class II directors and passed several other key proposals, including a substantial increase in authorized capital stock and an update to incorporate new Delaware law provisions for officer exculpation. Shareholders also ratified the appointment of Ernst & Young LLP as the auditor for the upcoming fiscal year and endorsed the executive officers’ compensation on an advisory basis.
Learn more about SYRS stock on TipRanks’ Stock Analysis page.